GHK-Cu + KPV Blend: Naming, Formulations and What the COA Should Show
The two-peptide preparation of GHK-Cu and KPV is sold under at least five different naming conventions and in two different compositions — 50 mg / 10 mg and 50 mg / 20 mg — with no standardisation between suppliers. It has no community-adopted name in the way GLOW and KLOW do, and at least one vendor markets it using a name belonging to a different four-peptide blend. Composition, not product name, is what identifies the material. The combination itself has no published literature; each peptide has its own. This article is a laboratory reference only, with no dosing guidance.
Search for the two-peptide blend of GHK-Cu and KPV and you will not find one product. You will find at least eight different names for what is, in most cases, the same vial — and two different formulations sold under those names without anyone flagging the difference.
This is a nomenclature problem, not a chemistry problem. But it makes the material genuinely hard to compare across suppliers, and it means a researcher reading two certificates of analysis may be reading about two different preparations. This article documents what the blend is actually called, why the naming fractured, where the formulations diverge, and what to look for on a COA for this particular combination — which is analytically more awkward than a single-peptide vial, for reasons worth understanding.
What suppliers actually call it
We surveyed around twenty vendors listing a GHK-Cu and KPV co-lyophilized preparation. The naming falls into five clusters:
| Naming pattern | Representative listings |
|---|---|
| GHK-Cu/KPV Blend | The clear plurality. Punctuation varies — slash, plus sign, or space — but the structure is identical. |
| GHK-Cu 50 mg / KPV 10 mg | Mass-first naming, where the quantities are the product name. |
| GHK/KPV Blend 50/10 | Drops the copper designation from the name entirely, which is a meaningful omission — GHK and GHK-Cu are not the same material. |
| KPV/GHK-Cu (10/50) | Reversed component order, listing the minor component first. |
| Proprietary names | Rare. We found a single vendor marketing it under a coined name rather than a descriptive one. |
The notable finding is the absence of a proprietary name that stuck. This blend has no GLOW, no KLOW — no community-adopted shorthand that vendors converged on independently.
“GHK” and “GHK-Cu” are not the same material
One naming variant deserves separating out, because it is the only one where the label difference corresponds to a real difference in what is in the vial.
GHK is the free tripeptide glycyl-L-histidyl-L-lysine. GHK-Cu is that tripeptide complexed with copper(II). They are different materials with different molecular weights, different appearance — the copper complex is blue, the free peptide is white — and different behaviour in the assays used to characterise them. Most of the research literature that suppliers cite concerns the copper complex specifically; the copper is not an incidental additive but part of the entity being studied.
Several listings for this blend name it “GHK/KPV”, dropping the copper designation. In the cases we examined the product does appear to be the copper complex — the CAS number given, the stated molecular weight, and the described blue powder all point to GHK-Cu. But the name alone does not tell you that, and at least one listing pairs a “GHK” product name with technical specifications that mix values belonging to the free peptide and the complex in the same table.
The practical rule: for a blend of this type, confirm the copper complex from the specifications and the described appearance, not from the product name. A white powder is a flag worth resolving before use.
Why this blend never got a name (and GLOW did)
The contrast with GLOW is instructive. GLOW — GHK-Cu with BPC-157 and TB-500 — and KLOW, which adds KPV as a fourth component, both acquired names that vendors now use as product categories rather than descriptions. Price and COA aggregators track them as distinct products.
Those names did not originate with a supplier. They emerged in research and enthusiast communities discussing the combinations, and vendors adopted the vocabulary afterwards. That direction of travel matters: a name imposed by a single seller rarely propagates, while a name the audience is already using gets adopted because it matches existing search behaviour.
The two-component GHK-Cu/KPV preparation never went through that process. It arrived as a supplier SKU, and so it is still described rather than named.
For orientation, the three preparations sit in a straightforward relationship:
| Preparation | Components | Total |
|---|---|---|
| GHK-Cu / KPV | GHK-Cu 50 mg · KPV 10 mg | 60 mg |
| GLOW | GHK-Cu 50 mg · BPC-157 10 mg · TB-500 10 mg | 70 mg |
| KLOW | GHK-Cu 50 mg · BPC-157 10 mg · TB-500 10 mg · KPV 10 mg | 80 mg |
The two-component blend is not a reduced KLOW in any formal sense — they are separate preparations — but it does contain the same two components KLOW carries alongside BPC-157 and TB-500. That relationship is presumably what makes the “Klow Stack” mislabelling tempting, and it is also why the naming confusion matters: the four-peptide and two-peptide preparations differ by 20 mg of material and two entire compounds.
One visible consequence: at least one vendor now markets its two-peptide GHK-Cu/KPV vial using “Klow Stack” in its page copy. KLOW is a four-peptide blend — BPC-157, GHK-Cu, TB-500 and KPV. Applying that label to a two-component preparation is inaccurate, and a researcher who orders on the strength of the heading receives something other than what the name denotes. It is a reasonable illustration of what happens when a product has no correct name to reach for.
The formulation split nobody mentions
More consequential than the naming: the blend is sold in two different compositions.
The majority of listings supply 50 mg GHK-Cu with 10 mg KPV — 60 mg total peptide mass. A meaningful minority supply 50 mg GHK-Cu with 20 mg KPV — 70 mg total, and double the KPV content.
Both are sold as “GHK-Cu/KPV Blend”. Neither is wrong, but they are not interchangeable, and the ratio of the two components differs by a factor of two. Any comparison across suppliers — of price per milligram, of purity, of anything — is invalid unless the composition is checked first. When a listing gives only the blend name without the masses, that is the first thing to resolve.
The preparation Condor Research supplies is the 50 mg / 10 mg configuration, 60 mg total — see GHK-Cu + KPV Blend for the full specification.
The two components
GHK-Cu (glycyl-L-histidyl-L-lysine complexed with copper(II)) is a copper-binding tripeptide that occurs naturally in human plasma. Its research profile centres on extracellular-matrix biology: analysis of gene-expression data has been used to argue for broad regulatory involvement in tissue remodelling and repair pathways (PMID 29986520). It has also been examined in the context of oxidative stress and copper homeostasis (PMID 22666519), in orthopaedic repair models (PMID 25731775), and more recently in an experimental colitis model (PMID 40672369).
KPV (Lys-Pro-Val) is the C-terminal tripeptide fragment of α-melanocyte-stimulating hormone. The anti-inflammatory activity of the α-MSH C-terminus has been dissected pharmacologically (PMID 12750433), and KPV has been characterised in murine inflammatory bowel disease models (PMID 18092346), including work identifying PepT1-mediated uptake as a route of entry into intestinal epithelial cells (PMID 18061177). Signalling in human keratinocytes has been examined separately (PMID 15102092).
Worth stating plainly, because most listings do not: the combination itself has not been studied. The literature above describes each peptide separately, largely in vitro or in animal models. There is no published work characterising the two peptides together, and no basis in the literature for claims about synergy between them. A researcher acquiring the blend is acquiring a convenience preparation of two separately characterised materials, not a studied combination.
Why the COA is harder here
This is the part that distinguishes a two-component copper-containing vial from an ordinary single-peptide one, and it is worth understanding before comparing certificates.
Copper(II) is redox-active. Metal-catalysed oxidation is a recognised degradation pathway in peptide and protein formulations, characterised in detail for other peptide and protein formulations (PMID 27435200). In practice the risk here is lower than it first appears: KPV is Lys-Pro-Val, containing no cysteine, methionine or tryptophan — the residues most vulnerable to oxidative modification. Its stability in aqueous systems has been assessed with a stability-indicating HPLC method (PMID 25298219). So KPV is a reasonable partner for a copper-containing preparation from a stability standpoint.
The analytical difficulty is separate from the stability question. In a co-lyophilized vial, purity and content must be established per component, and the copper complex complicates chromatographic analysis relative to a clean single-peptide assay. A certificate reporting one aggregate purity figure for “the blend” is not telling you what you need to know: a 99% figure could describe a vial where one component is under-filled.
What a useful certificate for this preparation reports:
- Content and purity stated separately for GHK-Cu and for KPV — not a single combined number.
- Measured content against label claim for each, so under-fill of the minor component is visible. This matters most for KPV, which at 10 mg is a sixth of the vial mass.
- Identity confirmation by mass spectrometry for both components, not retention time alone.
- A batch identifier that ties to the vial in hand — a generic certificate for the product line is not batch documentation.
- Where copper is specified, elemental analysis rather than an inference from the peptide assay.
Vendors vary considerably on this. Some publish full batch-specific analysis including endotoxin and elemental impurity screening; others state “third-party tested” without a document behind it. That distinction is more informative than any difference in the product name.
Purity is not content, and the published numbers show it
This is the single most common misreading of a peptide certificate, and for this blend there is public evidence sitting on vendor pages that illustrates it exactly.
Purity answers: of the material present, what fraction is the intended compound? Content answers: how many milligrams are actually in the vial? A preparation can be 99.8% pure and still be materially short of its label claim, because those two figures measure different things. Purity is a ratio; content is an absolute quantity.
Two examples, both taken from figures the vendors publish themselves:
- A European vendor selling a 50 mg / 20 mg preparation publishes batch analysis from an accredited Czech laboratory reporting purity above 99.8% for GHK-Cu and 99.3% for KPV — alongside assay results of 47.9 mg against the 50 mg claim and 19.5 mg against the 20 mg claim. Near-perfect purity, roughly 4% and 2.5% under label on content.
- A US vendor selling a 50/10 preparation states a purity average of 99.974% and lists a current batch at 44.80 mg GHK-Cu and 9.76 mg KPV — around 10% under label on the major component. The same page separately describes an average across certificates of 52.865 mg and 13.30 mg, figures that do not reconcile with the batch numbers shown immediately above them.
Worth being clear about what these examples do and do not show. The first vendor is doing the right thing: publishing measured content against label claim is exactly the transparency a certificate exists to provide, and a result within a few percent of claim is an unremarkable, honest outcome. It appears here not as a criticism but because it is one of the few places where the numbers are actually visible. The second case is a documentation problem — two contradictory sets of figures on one page — rather than a demonstrated deficiency in the material.
The lesson is for the reader, not the seller: a headline purity percentage tells you nothing about how much peptide you received. For a blend, this matters most for the minor component. KPV at 10 mg is one sixth of a 60 mg vial; a shortfall there is proportionally invisible in any figure computed across the vial as a whole. If a certificate reports only purity, it has answered the easier question.
What happens after reconstitution
One further point specific to this pairing. The stability discussion above concerns the lyophilized powder, which is the stable state. In solution the picture is different, and it is the state in which the two peptides actually coexist with dissolved copper.
KPV in aqueous solution has been characterised with a stability-indicating HPLC method developed for exactly this purpose (PMID 25298219), which is the kind of method required to distinguish intact peptide from its degradation products rather than simply measuring what is present. Published work on the two peptides together in solution does not exist, so the behaviour of the reconstituted blend over time is not documented anywhere in the literature.
In the absence of that data, the conservative handling assumptions are the ordinary ones: reconstitute close to the point of use, keep the solution cold and dark, and avoid repeated freeze-thaw cycles. Suppliers commonly state a 30-day refrigerated window for reconstituted material; that figure is a general convention for lyophilized peptides, not a measured result for this combination, and it is worth reading it as such.
Practical summary
If you are comparing suppliers for this material:
- Confirm the composition before anything else. 50/10 and 50/20 are both sold as the same thing.
- Ignore the product name. It carries no information — the same vial appears under at least five naming conventions, and at least one vendor uses a name belonging to a different four-peptide blend.
- Check that it is the copper complex, from the specifications and the blue appearance rather than from the name.
- Read content, not just purity. They are different measurements, and only content tells you how much peptide is in the vial. Require both, per component.
- Require per-component figures on the certificate. An aggregate purity number for a two-component vial is not a meaningful specification.
- Regard the combination as unstudied, in the vial and in solution. Each peptide has a literature; the pairing does not.
None of this is exotic diligence. It is the ordinary reading of a certificate — the only unusual thing about this particular preparation is how many of the listings selling it make that reading harder than it needs to be.
All materials referenced are supplied for laboratory research use only (in vitro). Not for human or veterinary use, administration, or consumption. Not a medicine, food, supplement, cosmetic, or medical device. References cited describe in vitro and animal-model research and are provided for scientific context only.
- The same GHK-Cu and KPV vial is sold as "GHK-Cu/KPV Blend", "GHK-Cu 50mg / KPV 10mg", "GHK/KPV Blend", "KPV/GHK-Cu" and under coined vendor names, with no convention shared across the market.
- Two different compositions circulate under identical names: 50 mg / 10 mg (60 mg total) and 50 mg / 20 mg (70 mg total), which makes cross-supplier price and purity comparison invalid unless composition is confirmed first.
- Unlike GLOW and KLOW, this preparation never acquired a community-adopted name, because it arrived as a supplier SKU rather than emerging from research discussion.
- At least one vendor applies the "Klow Stack" label to a two-component vial, although KLOW denotes a four-peptide blend of BPC-157, GHK-Cu, TB-500 and KPV.
- GHK and GHK-Cu are different materials — the free tripeptide and its copper(II) complex — and several listings drop the copper designation from the product name.
- Purity and content are different measurements: published vendor figures show preparations at over 99.8% purity that are simultaneously several percent under label claim on measured content.
- For a co-lyophilized two-component vial, a certificate should report content and purity separately for each component, since an aggregate figure cannot reveal under-fill of the minor component.
- No published work characterises GHK-Cu and KPV together, either lyophilized or in solution, so the behaviour of the reconstituted blend over time is undocumented.